Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][3] - Positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented at the CNS Summit 2024 [1] Presentation Details - The poster presentation titled "Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine" will take place on November 12th from 5:00 - 7:00 PM ET [2] - Dr. Jan Sedway from WCG Clinical will be the presenter [2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]